Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

Capricor Therapeutics (NASDAQ:CAPR) had its target price boosted by analysts at Cantor Fitzgerald from $25.00 to $30.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 61.20% from the company’s previous close.

A number of other research firms have also recently weighed in on CAPR. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock opened at $18.61 on Thursday. The stock has a market cap of $845.08 million, a P/E ratio of -17.56 and a beta of 4.00. The stock’s fifty day moving average is $15.21 and its 200 day moving average is $8.46. Capricor Therapeutics has a one year low of $2.87 and a one year high of $23.40.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The stock was acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 12.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of the business. Barclays PLC lifted its position in Capricor Therapeutics by 106.6% during the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock valued at $552,000 after purchasing an additional 18,724 shares during the last quarter. Sphera Funds Management LTD. bought a new position in shares of Capricor Therapeutics in the 3rd quarter valued at about $938,000. State Street Corp grew its position in Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after acquiring an additional 111,291 shares in the last quarter. Sassicaia Capital Advisers LLC bought a new stake in Capricor Therapeutics during the third quarter worth approximately $192,000. Finally, Point72 Asset Management L.P. purchased a new stake in Capricor Therapeutics during the third quarter valued at approximately $3,806,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.